Trauma newsround – 05/07/2013

05 July 2013

This week, Major Trauma Centres improve patient outcomes in England, a ground-breaking face transplant patient prospers and a new drug trial for treating brain injury recruits its first patient in Israel.

 

Major Trauma Centres improve patient outcomes

Results from a national audit by the Trauma Audit and Research Network (TARN) show that 1 in 5 patients who would have died before the networks are now surviving severe injuries, thanks to the introduction of Major Trauma Centres (MTCs) a year ago.

SRMRC is based at the Queen Elizabeth Hospital Birmingham, one of three MTCs in the West Midlands, and is helping to develop new techniques for treating patients who have suffered a major trauma.

Face transplant patient prospers

A year after receiving a completely new face, Richard Lee Norris is recovering well and describes the results as “a miracle”. Mr Norris had become a recluse in the 15 years since he suffered devastating injuries when a shotgun accidentally discharged in his face.

SRMRC is carrying out vital research into the reconstruction and regeneration of tissues after injury.

US company begins trial of new brain injury drug

US pharmaceutical company Oxygen Biotherapeutics has announced the enrollment of the first subject in the second cohort of the STOP-TBI trail, which is an international clinical trial to investigate the safety and tolerability of a drug called Oxycyte in patients with severe, non-penetrating traumatic brain injury.

The patient was enrolled in Israel at the Rambam Health Care Campus, which is the only Level 1 trauma center in the north of Israel.

SRMRC and the Rambam Medical Centre are among the world’s leading recruiters to the SyNAPSe trial, which is also looking at severe, non-penetrating traumatic brain injury.

Pennsylvania man tells of his experience on brain injury trial

Patient Lester Tally suffered a severe traumatic brain injury in a car accident and was enrolled in the SyNAPSe trial, which is examining the use of a hormone called progesterone to help patients recover from such injuries.

SRMRC is one of the world’s leading recruiters to this trial.